Key Events This Week
Feb 09: Q2 FY26 results reveal strong profitability
Feb 10: Intraday high of Rs.5,150 with 8.39% surge
Feb 12: Price correction amid Sensex decline
Feb 13: Week closes at Rs.5,034.45 (-1.84% on day)
Strong Q2 FY26 Results Spark Early Week Rally
On 9 February 2026, Pfizer Ltd announced its Q2 FY26 results, highlighting strong profitability that overshadowed lingering valuation concerns. The market responded positively, with the stock closing at Rs.4,760.60, up 3.62% from the previous close. This robust earnings report set the tone for the week, signalling confidence in the company’s operational performance despite cautious sentiment around its valuation metrics.
Intraday Surge on 10 February Propels Stock to New Highs
The momentum accelerated on 10 February as Pfizer Ltd hit an intraday high of Rs.5,150, marking an 8.39% surge during the trading session. The stock opened with a gap up of 2.32% and maintained strong buying interest throughout the day, closing at Rs.4,964.80, a 4.29% gain. This performance significantly outpaced the Pharmaceuticals & Biotechnology sector and the broader Sensex, which rose modestly by 0.25% that day. The heightened volatility and volume underscored active trading and investor enthusiasm following the earnings release.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Midweek Correction Reflects Broader Market Weakness
Following the strong gains earlier in the week, Pfizer Ltd experienced a pullback on 12 February, closing at Rs.5,129.05, down 1.39%. This decline coincided with a broader market correction as the Sensex fell 0.56% amid profit-taking and sector rotation. Despite the setback, the stock remained well above its opening price for the week, maintaining a positive trend relative to the market.
Week Ends with Slight Decline Amid Market Sell-Off
On 13 February, Pfizer Ltd closed at Rs.5,034.45, down 1.84% on the day, as the Sensex declined sharply by 1.40%. The stock’s retreat mirrored the broader market’s negative sentiment, which was influenced by macroeconomic concerns and profit booking. Nonetheless, Pfizer’s weekly gain of 9.58% highlights its resilience and relative strength compared to the Sensex’s 0.54% loss over the same period.
Is Pfizer Ltd. your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Daily Price Comparison: Pfizer Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-09 | Rs.4,760.60 | +3.62% | 37,113.23 | +1.04% |
| 2026-02-10 | Rs.4,964.80 | +4.29% | 37,207.34 | +0.25% |
| 2026-02-11 | Rs.5,201.35 | +4.76% | 37,256.72 | +0.13% |
| 2026-02-12 | Rs.5,129.05 | -1.39% | 37,049.40 | -0.56% |
| 2026-02-13 | Rs.5,034.45 | -1.84% | 36,532.48 | -1.40% |
Key Takeaways from the Week
Positive Signals: Pfizer Ltd’s 9.58% weekly gain significantly outperformed the Sensex’s 0.54% decline, driven by strong quarterly earnings and a robust intraday surge on 10 February. The stock’s ability to trade above key moving averages and deliver an attractive dividend yield of 3.46% supports its technical and fundamental strength. The intraday volatility and volume spikes indicate active investor interest and confidence in the company’s growth prospects.
Cautionary Notes: Despite the strong start, the stock faced profit-taking pressure midweek and ended with two consecutive days of decline, reflecting broader market weakness and valuation concerns. The current Mojo Grade of ‘Sell’ with a score of 37.0 suggests a cautious stance, highlighting potential risks amid the rally. Investors should note the stock’s mid-tier market capitalisation grade and monitor market conditions closely.
Conclusion
Pfizer Ltd’s performance this week underscores its resilience and relative strength within the Pharmaceuticals & Biotechnology sector. The combination of strong quarterly results and a significant intraday rally propelled the stock to new highs, outpacing the broader market. However, the subsequent correction and cautious Mojo Grade indicate that investors should remain vigilant amid ongoing market volatility. Overall, Pfizer Ltd demonstrated a compelling blend of fundamental robustness and technical momentum during the week ending 13 February 2026.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
